Regenxbio
RGNX on Nasdaq. REGENXBIO licenses gene therapy technology to drugmakers and develops treatments for patients. Market value $505m.
Price checks use the past 12 months to September 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
Capital spending looks too small to be complete, so we leave free cash flow out.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Look carefully before going further
Why it could be worth it
Read the warning sign in its own filings
This is not advice. Check the numbers below.
We could not compute this from the filings.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 34 of 100. Price score: 16 of 100. Our list needs 70 on quality and 60 on price.
$7.16 a share, 31% above its 1-year low
Over the past year the price has ranged from $5.45 to $16.19.
Pays no dividend
Prices from Friday’s close (20 November).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $470m | $113m | $90m | $83m | $170m |
| Operating margin | |||||
| Operating margin | 34.0% | -233.2% | -297.1% | -280.0% | -94.6% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.04bn | 0.04bn | 0.05bn | 0.05bn | 0.07bn |
Health checks
- Free cash flow positive1 of 3 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)2 of 7 checks we could run
- Profit backed by cash (accruals)No
- DebtUnknown
- Revenue growth, five yearsSlow, 2.0% a year
- Buying back its own sharesNo, 53% more shares since 2021
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $9 million last quarter, down 69% on a year ago.
- A loss of $41 million, compared with a loss of $62 million a year ago.
- It loses 96 cents on each $1 of sales, compared with 96 cents a year earlier.
- 26% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 2 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| December 2024 | $21m |
| March 2025 | $89m |
| June 2025 | $21m |
| September 2025 | $30m |
| December 2025 | $30m |
| March 2026 | $6m |
| June 2026 | $108m |
| September 2026 | $9m |
| Quarter to | Amount |
|---|---|
| December 2024 | -$51m |
| March 2025 | $6m |
| June 2025 | -$71m |
| September 2025 | -$62m |
| December 2025 | -$67m |
| March 2026 | -$90m |
| June 2026 | $23m |
| September 2026 | -$41m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 5 March 2026
- Next quarterly (estimated, 10-Q)
- 4 February 2027
Who owns it
None of the long-term investors we follow own it. 165 funds in all.
Sold out this quarter
- Voss CapitalTravis CockeSold out
Largest holders overall
- BlackRock$77mAdded
- Redmile Group$52m
- State Street$36mAdded
- JPMorgan Chase$26mCut
- Vanguard Capital Management$25mAdded
- Morgan Stanley$23mCut
- Goldman Sachs Group$17mCut
- AQR Capital Management$17mAdded
- Vanguard Portfolio Management$16mAdded
- Marshall Wace, LLP$15mNew
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
3 investors own more than 5%.
- Redmile Group, LLCPassive investorat least 9.9%(filed with 2 related holders)Since 30 June 2025
- BlackRock, Inc.Passive investor7.3%−3.7 ptsSince 31 March 2025
- JPMORGAN CHASE & CO.Passive investor5.3%+0.9 ptsSince 30 September 2026
- STATE STREET CORPORATIONPassive investorSold down below 5%Since 30 September 2026
- BlackRock Portfolio Management LLCPassive investorSold down below 5%Since 31 December 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
Redmile Group, LLC Passive investor | at least 9.9% (filed with 2 related holders) | 30 June 2025 | |
BlackRock, Inc. Passive investor | 7.3%−3.7 pts | 31 March 2025 | |
JPMORGAN CHASE & CO. Passive investor | 5.3%+0.9 pts | 30 September 2026 | |
STATE STREET CORPORATION Passive investor | Sold down below 5% | 30 September 2026 | |
BlackRock Portfolio Management LLC Passive investor | Sold down below 5% | 31 December 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $949,381 of shares on the open market. 1 sold $939,970, $251,215 of it under preset trading plans.
- Ciongoli Gregory AustinDirectorBought
- Date
- 27 August 2026
- Shares
- 53,407
- Price
- $9.36
- Value
- $499,676
- Ciongoli Gregory AustinDirectorBought
- Date
- 26 August 2026
- Shares
- 49,196
- Price
- $9.14
- Value
- $449,706
- PAKOLA STEVEChief Medical OfficerSoldunder a preset trading plan
- Date
- 2 July 2026
- Shares
- 2,161
- Price
- $13.64
- Value
- $29,476
- PAKOLA STEVEChief Medical OfficerSold
- Date
- 1 July 2026
- Shares
- 36,725
- Price
- $12.86
- Value
- $472,284
- PAKOLA STEVEChief Medical OfficerSold
- Date
- 29 June 2026
- Shares
- 19,608
- Price
- $11.04
- Value
- $216,472
- PAKOLA STEVEChief Medical OfficerSoldunder a preset trading plan
- Date
- 11 May 2026
- Shares
- 15,309
- Price
- $11.02
- Value
- $168,705
- PAKOLA STEVEChief Medical OfficerSoldunder a preset trading plan
- Date
- 10 March 2026
- Shares
- 5,124
- Price
- $10.35
- Value
- $53,033
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 27 August 2026 | Ciongoli Gregory Austin Director | Bought | 53,407 | $9.36 | $499,676 |
| 26 August 2026 | Ciongoli Gregory Austin Director | Bought | 49,196 | $9.14 | $449,706 |
| 2 July 2026 | PAKOLA STEVE Chief Medical Officer | Sold under a preset trading plan | 2,161 | $13.64 | $29,476 |
| 1 July 2026 | PAKOLA STEVE Chief Medical Officer | Sold | 36,725 | $12.86 | $472,284 |
| 29 June 2026 | PAKOLA STEVE Chief Medical Officer | Sold | 19,608 | $11.04 | $216,472 |
| 11 May 2026 | PAKOLA STEVE Chief Medical Officer | Sold under a preset trading plan | 15,309 | $11.02 | $168,705 |
| 10 March 2026 | PAKOLA STEVE Chief Medical Officer | Sold under a preset trading plan | 5,124 | $10.35 | $53,033 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Regenxbio’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 5 Mar 2026, plus the 10-Q filed 5 Nov 2026 and 11 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern within 12 months from the date these consolidated financial statements were issued.”
Show the full paragraph
As of September 30, 2026, the Company had cash, cash equivalents and marketable securities of $ 251.0 million. In October 2026, the Company received a payment of $ 39.0 million pursuant to a settlement agreement with Sarepta Therapeutics, Inc. (Sarepta). Please refer to Note 8 for further information regarding the settlement agreement with Sarepta. Management believes the Company's cash, cash equivalents and marketable securities as of September 30, 2026, along with the settlement proceeds received in October 2026, are sufficient to fund operations into the late fourth quarter of 2027. This estimate is based on the Company's current operating plan and excludes the potential effects of any future financings or material milestone payments that may be received under the Company's licensing and collaboration arrangements. The Company has based this estimate on assumptions that may prove to be wrong, and it could exhaust its capital resources sooner than expected. These conditions raise substantial doubt about the Company's ability to continue as a going concern within 12 months from the date these consolidated financial statements were issued. The Company’s ability to continue as a going concern will depend heavily on the successful development, approval and commercialization of its product candidates and its ability to raise additional capital to fund its operations. If the Company is unable to raise capital sufficient to meet its working capital needs in the future, it may be forced to delay expenditures, reduce the scope of its development activities or make other changes to its operating plans.
From the 10-Q filed 5 November 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- Sales have barely grown: 2.0% a year.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.